The Fort Worth Press - Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

USD -
AED 3.672502
AFN 66.503533
ALL 80.653395
AMD 365.190533
AOA 917.000035
ARS 1498.997502
AUD 1.414807
AWG 1.80125
AZN 1.703011
BAM 1.692154
BBD 2.008721
BDT 123.455081
BHD 0.3761
BIF 2985.970817
BMD 1
BND 1.277984
BOB 11.853211
BRL 5.0847
BSD 0.997309
BTN 94.901089
BWP 13.461555
BYN 2.969692
BYR 19600
BZD 2.005779
CAD 1.395555
CDF 2262.48083
CHF 0.808945
CLF 0.023198
CLP 913.000117
CNY 6.747602
CNH 6.74499
COP 3157.69
CRC 453.361712
CUC 1
CUP 26.5
CVE 95.398565
CZK 20.99955
DJF 177.598394
DKK 6.46983
DOP 58.218911
DZD 132.930608
EGP 49.862606
ERN 15
ETB 160.971007
EUR 0.865461
FJD 2.209039
FKP 0.741752
GBP 0.740945
GEL 2.610132
GGP 0.741752
GHS 11.701051
GIP 0.741752
GMD 73.49797
GNF 8759.111457
GTQ 7.609218
GYD 208.606894
HKD 7.84545
HNL 26.731037
HRK 6.520949
HTG 130.40262
HUF 314.141017
IDR 17787
ILS 3.002101
IMP 0.741752
INR 95.255497
IQD 1306.448752
IRR 1375549.999767
ISK 123.419864
JEP 0.741752
JMD 158.382433
JOD 0.708998
JPY 158.363496
KES 129.350453
KGS 87.450284
KHR 4050.85633
KMF 425.999989
KRW 1417.039596
KWD 0.30876
KYD 0.831109
KZT 467.406398
LAK 22517.541811
LBP 89309.055987
LKR 334.518649
LRD 180.013843
LSL 16.202317
LTL 2.95274
LVL 0.60489
LYD 6.343603
MAD 9.294994
MDL 17.342816
MGA 4255.889809
MKD 53.263787
MMK 2099.549591
MNT 3594.253507
MOP 8.059058
MRU 40.09223
MUR 46.999966
MVR 15.450279
MWK 1729.34998
MXN 17.146945
MYR 4.088205
MZN 63.905023
NAD 16.202107
NGN 1361.990169
NIO 36.701693
NOK 9.509905
NPR 151.845026
NZD 1.697605
OMR 0.384502
PAB 0.997314
PEN 3.377444
PGK 4.407375
PHP 60.727982
PKR 276.877947
PLN 3.72035
PYG 5930.040405
QAR 3.64559
RON 4.542397
RSD 101.532942
RUB 82.275776
RWF 1466.50401
SAR 3.744756
SBD 8.065696
SCR 14.71782
SDG 600.543302
SEK 9.48485
SGD 1.279203
SLE 24.616069
SOS 569.989877
SRD 37.8665
STD 20697.981008
STN 21.197622
SVC 8.726386
SZL 16.199029
THB 32.977027
TJS 9.200175
TMT 3.51
TND 2.92983
TRY 47.717896
TTD 6.759762
TWD 32.219101
TZS 2642.563019
UAH 44.66703
UGX 3714.372216
UYU 40.144833
UZS 11927.514351
VES 755.762401
VND 26142
VUV 119.366412
WST 2.733717
XAF 567.53013
XAG 0.015601
XAU 0.00023
XCD 2.70255
XCG 1.797449
XDR 0.705825
XOF 567.53013
XPF 103.182603
YER 238.400752
ZAR 16.15735
ZMK 9001.206991
ZMW 18.824028
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • RELX

    0.0485

    35.52

    +0.14%

  • VOD

    0.1900

    16.19

    +1.17%

  • BCE

    -0.0200

    22.75

    -0.09%

  • RIO

    1.4500

    101.1

    +1.43%

  • NGG

    0.4700

    80.88

    +0.58%

  • BCC

    2.3400

    86.6

    +2.7%

  • JRI

    0.1500

    12.81

    +1.17%

  • BTI

    0.6000

    59.33

    +1.01%

  • GSK

    0.7900

    52.96

    +1.49%

  • BP

    -0.6000

    41.63

    -1.44%

  • AZN

    1.4100

    161.42

    +0.87%

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com.

Text size:

Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum

When: Thursday, March 12, 2026 at 2:00 PM Eastern

Registration link for conference: Click Here

Replay: A replay of the webcast will be available following the conclusion of the conference.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the March 2026 conference listed above. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

X.Silva--TFWP